Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants

• Main Authors: Suzanne M. Garland (Author), Manjula Anagani (Author), Neerja Bhatla (Author), Sukanta Chatterjee (Author), Sanjay Lalwani (Author), Cecil Ross (Author), Thomas Group (Author), Jianxin Lin (Author), Alain Luxembourg (Author), Anuj Walia (Author), Yingmei Tu (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) and 9-valent HPV (9vHPV; HPV6/11/16/18/31/33/45/52/58) vaccines have demonstrated efficacy, immunogenicity, and safety in international clinical trials. We report outcomes from three completed clinical trials in India: a single-arm study (V...